Blueprint Medicines announces avapritinib presentations at EAACI/EHA meetings

Blueprint Medicines “announced multiple upcoming datasets across two key conferences that reinforce the significant real-world burden of systemic mastocytosis, and highlight the durable clinical outcomes of AYVAKIT/AYVAKYT, or avapritinib, across the spectrum of the disease. The presentations, which build on over a decade of pioneering research with clinical experts and patient advocates, will be reported at the following meetings: European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, May 31 to June 3 and European Hematology Association 2024 (EHA24) Hybrid Congress, June 13 to 16.” “Our data reinforce the efficacy and safety of prolonged durations of AYVAKIT therapy, and highlight the urgency to diagnose and treat patients living with systemic mastocytosis,” said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. “Based on unprecedented clinical datasets and the strength of our ongoing commercial launches in the U.S. and Europe, we have made significant progress toward establishing AYVAKIT as the global standard of care. We look forward to continued collaboration with the SM community to redefine what ‘well-controlled’ means for patients across the spectrum of the disease.”